Skip to content

Loading...

Search for:

Search

About
Our Science
Diseases
Development Program
- Resomelagon
  - Inflammatory and Autoimmune Diseases
    
    RA: The BEGIN Study
    
    RA: The EXPAND Study
    
    RA: The RESOLVE Study
    
    RA: The ADVANCE Study
    
    iMN: SynAct-CS003
  - Host-Directed Therapy in Viral Infections
    
    COVID-19: RESOVIR-1
    
    Dengue Fever: RESOVIR-2
- TXP-11
Investors
News & Media

ENG
SVE

Search for:

Search

SynAct Pharma publishes Q3 2020 interim report (in Swedish)

November 13, 2020 - Regulatory

Documents

Delårsrapport Q3 2020 SynAct Pharma AB - Rapport November 13, 2020 - Swedish

News & Media

News and Press Releases
SynAct in the Media
Slide Decks and Presentations
Image Bank

SynactPharma-white

Advancing medicine trough
melanocortin activation

SynAct Pharma AB (publ)
Scheelevägen 2
SE-223 63 Lund
Sweden

Synact Pharma ApS
Dronninggårds Alle 136
2840 Holte
Denmark

About
Our Science
Diseases
Development Program
Investors
News & Media

Privacy Policy
Cookies

Get the latest news follow us on Linkedin

© 2025 SynAct Pharma AB. All right reserved.